• The company has issued zero common shares since October 2023, marking a decisive break from typical OTC dilution patterns.
• A multi-year share repurchase program has retired more than 20 million shares while authorized shares have been reduced by 60%.
• Earth Science Tech is funding operations and acquisitions through cash flow while legally restricting its future ability to dilute shareholders.

In the microcap market, capital formation is often synonymous with dilution. Companies raise money by issuing new shares, frequently at the expense of long-term shareholders, creating a cycle where growth in operations does not translate into growth in per-share value. Against that backdrop, capital discipline itself becomes a differentiator, and increasingly, a signal of management intent.

Earth Science Tech (OTCID: ETST) has taken an approach that runs counter to long-standing norms in the OTC market. Rather than expanding its share count to fund operations, the company has spent the past two years reversing dilution, tightening its capital structure, and shrinking both its outstanding and authorized shares.

The Inflection Point: October 2023

The most consequential event in Earth Science Tech’s recent capital history is not tied to revenue or an acquisition announcement, but to a single issuance date. According to SEC filings, the last issuance of common stock occurred in October 2023 and was made to an employee. Since that point, the company has issued no additional common shares.

That pause has now extended across multiple reporting periods, including a phase marked by operational expansion and subsidiary integration. During that time, Earth Science Tech funded its activities through operating cash flow rather than equity issuance, effectively halting the incremental share count expansion that characterizes much of the microcap landscape.

From Neutral to Reverse: The Buyback Strategy

In early 2024, the company shifted from simply holding the line on dilution to actively reducing its share count. On January 29, 2024, Earth Science Tech initiated a share repurchase program, signaling a fundamental change in capital allocation priorities.

The program was later expanded by the board in August 2025, increasing the authorized repurchase amount to $10 million and extending the program through December 2027. Public filings confirm that more than 20 million shares have already been repurchased and retired.

This approach creates a structural dynamic that differs meaningfully from typical OTC issuers. While many companies rely on equity issuance to bridge operating gaps, Earth Science Tech has chosen to return capital to shareholders by reducing the public float, allowing operating performance to accrue to a smaller base of outstanding shares.

Reducing the Ceiling, Not Just the Float

Beyond buybacks, Earth Science Tech has taken the less common step of reducing its authorized share count, a move that permanently constrains future dilution.

In 2024, the company amended its Articles of Incorporation to reduce authorized common shares from 750 million to 350 million, eliminating more than half of the potential share supply in a single action. The following year, management further reduced the authorized count to 300 million shares.

This two-stage reduction is notable not only for its scale, but for its implications. Authorized shares represent a company’s maximum potential equity issuance capacity. By lowering that ceiling, Earth Science Tech has legally limited its ability to issue new shares, signaling confidence that future capital needs can be met without relying on equity markets.

Alignment and Ownership Structure

Management ownership further reinforces the capital discipline narrative. Insiders collectively hold approximately 47% of the outstanding shares, representing roughly 138.6 million shares, and filings indicate continued open-market purchases.

This ownership concentration aligns management incentives with long-term per-share value creation rather than short-term financing flexibility. Combined with the absence of recent dilution, it places Earth Science Tech in a distinct minority among OTC-listed companies.

Operating Platform Overview

Earth Science Tech operates as a strategic holding company with controlling interests across several healthcare-related verticals. Its portfolio includes compounding pharmaceuticals, telemedicine platforms, healthcare services, and real estate development.

Subsidiaries include RxCompoundStore.com, a licensed compounding pharmacy operating across multiple states; telemedicine platforms such as Peaks Curative, DOConsultations, and Las Villas Health Care, which serve both English- and Spanish-speaking patient populations; Mister Meds, a physician-founded pharmacy focused on wellness medicine; and Avenvi, a real estate development firm. The company also holds an 80% interest in MagneChef, a direct-to-consumer brand with proprietary intellectual property.

A Structural Outlier in the OTC Market

Viewed collectively, the numbers tell a clear story. No new shares have been issued since October 2023. Ongoing share repurchases, reducing the float. Authorized shares cut from 750 million to 300 million. Significant insider ownership.

In a market where dilution is often assumed, Earth Science Tech has instead engineered structural scarcity in its equity. Whether that approach translates into long-term shareholder value will ultimately depend on operational execution, but from a capital structure standpoint, the company has already distinguished itself by doing what few OTC issuers attempt, and even fewer sustain.

For more information, visit EarthScienceTech.com.

NOTE TO INVESTORS: The latest news and updates relating to ETST are available in the company’s newsroom at https://ibn.fm/ETST

• LIXTE’s lead compound, LB-100, targets PP2A, a central regulator of cancer cell survival and treatment resistance
• Clinical programs are designed to enhance existing immunotherapies and chemotherapies rather than replace them
• Multiple active trials across ovarian clear cell cancer, colon cancer, and soft tissue sarcoma support a platform approach

Despite decades of progress in oncology, many cancers remain resistant to treatment, not because therapies are unavailable, but because tumor cells adapt. Immunotherapies and chemotherapies can produce meaningful responses, yet durability and consistency remain challenges, particularly in aggressive or rare cancer subtypes. Increasingly, research is shifting toward approaches that improve how well existing treatments work, rather than introducing entirely new drugs.

That strategy defines LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT), a clinical-stage pharmaceutical company focused on enhancing established cancer therapies by targeting a fundamental biological pathway involved in tumor survival and resistance. Rather than developing standalone treatments, LIXTE is advancing a first-in-class approach designed to increase the effectiveness of chemotherapy and immunotherapy across multiple cancer indications.

Targeting PP2A: A Central Control Point

At the center of LIXTE’s strategy is protein phosphatase 2A, or PP2A, an enzyme that plays a critical role in regulating cell growth, DNA repair, and survival signaling. In many cancers, PP2A activity enables tumor cells to recover from the damage caused by treatment, contributing to resistance and disease progression.

LIXTE’s proprietary compound, LB-100, is a small-molecule PP2A inhibitor designed to temporarily disrupt these repair mechanisms at the moment when cancer cells are exposed to therapy. Preclinical research cited in the company’s presentation shows that this disruption can make tumor cells more vulnerable to chemotherapy and immunotherapy, increasing treatment effectiveness without introducing a new cytotoxic agent.

Importantly, LB-100 is not intended to act alone. Its role is to enhance existing treatments, aligning development with current standards of care and potentially simplifying clinical integration if efficacy is demonstrated.

A Safety Profile That Enables Combination Use

One of the key challenges in combination of oncology therapies is toxicity. According to LIXTE’s corporate materials, LB-100 has demonstrated a promising safety profile across two Phase 1 clinical trials, with doses associated with anti-cancer activity being well tolerated in patients.

The compound has also been supported by more than 25 published studies documenting anti-cancer activity across multiple tumor types. Manufacturing considerations are addressed through GMP production, and regulatory milestones include active IND status with the FDA and investigational approval in Europe.

This safety foundation is critical, as it allows LB-100 to be tested alongside immunotherapies and chemotherapies without compounding toxicity risk, a requirement for any enhancer-based oncology strategy.

Focus on Ovarian Clear Cell Cancer

LIXTE’s most advanced clinical program targets ovarian clear cell carcinoma, a rare and aggressive subtype of ovarian cancer known for poor responses to standard treatments. The company is conducting a Phase 1b/2 trial combining LB-100 with dostarlimab, a PD-1 immune checkpoint inhibitor.

The trial is sponsored by The University of Texas MD Anderson Cancer Center, with GSK providing support for the immunotherapy component. A second site was added at Northwestern University’s Robert H. Lurie Comprehensive Cancer Center, expanding enrollment capacity and geographic reach.

In December 2025, LIXTE announced plans to double enrollment from 21 to 42 patients, following successful completion of the initial cohort. Data from the first 21 patients is expected in the first half of 2026, representing a near-term clinical milestone.

Expanding Across Multiple Cancer Types

Beyond ovarian cancer, LIXTE is advancing additional clinical programs that apply the same PP2A-inhibition strategy across different tumor environments.

A metastatic MSI-low colon cancer trial is underway in collaboration with the Netherlands Cancer Institute and Roche, exploring whether LB-100 can convert immunologically “cold” tumors into ones that respond to immunotherapy. The trial design reflects preclinical findings that PP2A inhibition may increase neoantigen production and immune system engagement.

LIXTE has also completed enrollment in a Phase 1 study combining LB-100 with doxorubicin in advanced soft tissue sarcoma, a cancer with limited treatment advances over the past several decades. Results from this program are expected to provide additional insight into LB-100’s role alongside chemotherapy.

A Platform, Not a Single Asset

Taken together, LIXTE’s programs suggest a platform approach rather than a single-indication bet. Each trial tests the same biological hypothesis: that temporary PP2A inhibition can improve outcomes by weakening cancer cells’ defenses against therapy.

The company’s advisory network includes established oncology researchers and its clinical collaborations with institutions such as MD Anderson, Northwestern, and international cancer centers provide external validation of both the science and trial design.

Looking Ahead

LIXTE’s development path remains subject to the inherent risks of clinical-stage oncology, including trial outcomes and regulatory timelines. However, its focus on enhancing existing therapies positions the company within a growing segment of oncology research aimed at improving durability and response rather than reinventing treatment entirely.

As clinical data begins to emerge in 2026, those results will be central to determining whether PP2A inhibition can fulfill its promise as a broadly applicable enhancer across multiple cancer types.

For more information, visit the company website at https://lixte.com.

NOTE TO INVESTORS: The latest news and updates relating to LIXT are available in the company’s newsroom at ibn.fm/LIXT

• A Fox Business report offers a snapshot of how quickly robotics are moving into real-world operations
• Recent company updates reinforce that TechForce is focused on scaling, not just showcasing technology
• The company has outlined a manufacturing scale strategy tied to a broader roadmap, including scaling RaaS, expanding partnerships and supporting broader rollouts

When businesses cannot hire fast enough to keep operations running smoothly, the labor shortage stops being an abstract economic statistic and becomes a daily bottleneck that customers can feel. That pressure is now pushing service robots from novelty to necessity, as companies look for practical ways to keep facilities clean, move goods and maintain throughput without burning out scarce staff. Nightfood Holdings Inc. (OTCQB: NGTF), doing business as TechForce Robotics, is positioning itself for this moment by scaling an AI-driven service robotics platform built to take on repetitive, labor-intensive work that is increasingly difficult to fill with human labor.

A recent Fox Business report offers a snapshot of how quickly robotics is moving into real-world operations. The story profiles RobotLAB, a Texas-headquartered company with 36 locations across the United States and a catalog of more than 50 robot types, ranging from cleaning and customer-service units to security robots. The report describes robots being used across settings as varied as nursing homes, restaurants, hotels, warehouses and even emergency response scenarios, illustrating a key shift: Many organizations are no longer experimenting with robots for fun, they are deploying them to solve specific operational shortages.

The Fox Business piece also highlights why cleaning robots have become one of the most popular categories. The report notes that cleaning robots can cover extremely large footprints every day, and that hospitals, airports and supermarkets are adopting robots as they search for dependable ways to maintain standards despite staffing constraints. Fox frames the business case in plain terms: robots can take on “jobs that no one else wants to do,” allowing owners to keep operating even when hiring is difficult. The story also points to accelerating progress in humanoid robotics, observing that improvements in hardware and software are making robots more capable of understanding environments and performing complex tasks, which could expand the scope of automation over the next decade.

That is the context in which TechForce Robotics are focused. The company describes itself as an emerging robotics platform focused on deploying AI-powered automation across multiple industries, with hospitality as its initial sector of entry. The rationale maps closely to the labor-gap reality described in the Fox Business report. TechForce says its Robotics-as-a-Service (“RaaS”) approach is designed to address repetitive, labor-intensive tasks and other roles that are increasingly difficult for staff. Instead of treating robots as one-off equipment purchases, the RaaS model is positioned as an operating solution, with deployments designed to improve reliability and performance for customers while aligning ongoing service with recurring revenue.

Recent company updates reinforce that TechForce is focused on scaling, not just showcasing technology. In a December 2025 announcement, the company outlined a manufacturing scale strategy tied to its broader roadmap, including scaling Robotics-as-a-Service deployments, expanding enterprise partnerships and supporting broader rollouts across hospitality, food service, airports, venues and other large-footprint environments. The same release describes a vertically integrated model that combines robotics technology, real-world operating environments and scalable manufacturing, a structure meant to accelerate adoption as customer interest grows.

TechForce has also been developing new proprietary systems aimed at high-volume, labor-stressed environments. In another December 2025 release, the company announced a proprietary beverage-dispensing robotic platform called the Beverage Bot, designed to reduce wait times and capture revenue that can be lost when demand exceeds human staffing capacity during peak periods. The company describes the Beverage Bot as internally developed and intended to materially increase throughput in high-traffic venues, positioning it as a tool for both labor substitution and revenue optimization.

With labor constraints pushing robots into mainstream adoption, TechForce Robotics are committed to execution: scaling deployments, building repeatable customer outcomes and expanding product capability in ways that solve real bottlenecks. As the company works to deliver consistent performance through its Robotics-as-a-Service approach while scaling manufacturing and broadening its proprietary platform, it stands to benefit from a world that is quickly learning the same lesson across sectors: When labor is scarce and demand is rising, smart automation becomes the growth plan.

For more information, visit the company’s website at TechForceRobotics.com.

NOTE TO INVESTORS: The latest news and updates relating to NGTF are available in the company’s newsroom at http://ibn.fm/NGTF

• Power availability and control are emerging as binding constraints on AI data center growth, with efficient energy control now seen as critical to the financial viability of hyperscale AI campuses.
• GridAI focuses its AI-native software on energy orchestration rather than power generation or hardware, operating at the intersection of utilities, power markets, and large AI-driven electricity demand.
• The company’s technology manages energy flows outside the data center, across grid assets, storage, and on-site generation.

For much of the past decade, the investment narrative around artificial intelligence has revolved around semiconductors, cloud platforms, and talent. More recently, attention has shifted to data center capacity and the supply chains needed to support it. 

However, as AI workloads continue to scale, a different constraint has begun to assert itself more forcefully: electricity. Not electricity as a commodity, but electricity as a managed system, controlling how power is delivered, when it is available, and how it is managed under stress. As argued in a recent analysis on the economics of AI infrastructure, the power grid has become a central battleground for the next phase of AI growth (https://ibn.fm/9s6cs). GridAI Technologies (NASDAQ: GRDX), a company operating at the intersection of artificial intelligence and energy infrastructure, has positioned itself within that emerging fault line.

The company is developing grid and power-management software aimed at hyperscale AI data center campuses. Its core proposition is that the limiting factor for AI infrastructure is no longer only compute capacity, but the ability to control and optimize energy at scale.

This challenge is structural. Modern grids were designed for predictable demand patterns and centralized generation. AI data centers do not conform to that model. They operate continuously, draw large and variable loads, and increasingly cluster in regions where grid capacity is already strained. At the same time, electric vehicles, electrification of industry, and distributed energy resources are adding new layers of volatility.

Global capacity needs tied to these trends are projected to rise by more than 50 gigawatts by 2028. Meeting that demand through traditional grid upgrades alone would require years of planning, regulatory approval, and billions of dollars in capital. In the near term, the system must function with what already exists.

GridAI is targeting that gap. Rather than building power plants or transmission lines, the company focuses on orchestration software that allows existing assets to operate more flexibly. Its systems coordinate energy flows between grid connections, on-site generation such as reciprocating engines, battery energy storage systems (“BESS”), and, in some cases, renewable inputs like solar.

Crucially, this orchestration happens largely outside the data center itself. While AI servers equipped with GPUs create the underlying demand, GridAI is not managing GPU workloads. Instead, it operates at the interface between the data center campus and the broader energy ecosystem. Decisions are made in the context of fuel costs, grid pricing, and available revenue streams from real-time and day-ahead power markets or utility programs.

Many companies in the AI infrastructure stack focus inside the data center, optimizing compute utilization or thermal management. GridAI is addressing a different layer: how power is sourced, balanced, and monetized before it reaches the racks. From an economic perspective, that layer is gaining importance. Power constraints can delay data center deployments, inflate operating costs, or force operators into unfavorable long-term contracts. Software that improves visibility and control over energy inputs can therefore influence both capital planning and operating margins.

The company’s strategy reflects a broader shift in infrastructure markets. Historically, grid modernization meant physical expansion: more generation, more transmission, more steel in the ground. While those investments remain necessary, they are slow to deploy. Software-based control, by contrast, can scale faster and adapt in real-time to changing conditions.

GridAI frames its role as an intelligence layer that sits across assets that were never designed to work together dynamically. By coordinating dispatch, storage, and load management, the company aims to reduce congestion, manage volatility, and improve resilience without waiting for large-scale buildouts.

GridAI is also extending its reach beyond hyperscale campuses. The company describes applications that include delivering intelligence to households by orchestrating behind-the-meter devices and renewable assets. While data centers represent the most acute pressure point today, the underlying software architecture is intended to operate across multiple layers of the energy system.

For more information, visit the company’s website at www.Grid-AI.com.

NOTE TO INVESTORS: The latest news and updates relating to GRDX are available in the company’s newsroom at https://ibn.fm/GRDX

• The company signed a letter of intent to acquire Vivakor’s Oklahoma midstream and transportation assets for about $36 million.
• The transaction targets the Omega pipeline system serving the STACK play in Oklahoma.
• Assets generate fee-based revenue supported by a take-or-pay EBITDA guarantee.
• The deal would expand Olenox’s midstream presence and reduce exposure to commodity price swings.
• Management is pursuing an integrated energy model spanning upstream, midstream, services, and technology.

Olenox Industries (NASDAQ: OLOX), a vertically integrated energy company, is seeking to deepen its position in U.S. energy infrastructure with a proposed acquisition of Vivakor Inc.’s midstream business in Oklahoma. The company announced it has signed a non-binding letter of intent to acquire the midstream and transportation assets of CPE Gathering MidCon, LLC, a Vivakor subsidiary that owns and operates the Omega pipeline system in the Oklahoma STACK play (https://ibn.fm/1oC9H).

The transaction is valued at approximately $36 million and would be paid through a mix of cash, a promissory note, and common and preferred equity. The valuation is based on annual EBITDA of $4.56 million, supported by a take-or-pay guarantee from Vivakor. Olenox and Vivakor are working toward definitive agreements, with a targeted closing on or before March 31, 2026, subject to customary conditions.

The assets at the center of the proposed deal comprise the Omega system, an on-basin crude oil gathering, transportation, terminaling, and pipeline connection platform serving producers in the STACK region. The system provides gathering and transport to storage, blending facilities, and downstream pipeline injection points, offering producers an alternative to truck-based logistics and third-party terminaling.

Michael McLaren, Olenox’s chief executive officer, framed the acquisition as a step toward building predictable, infrastructure-driven cash flow. “Integrated midstream platforms like CPE Gathering generate durable, fee-based cash flows and provide critical infrastructure in established producing basins,” he said in the announcement. “The proposed acquisition of Vivakor’s Oklahoma midstream business would expand our presence in the STACK while positioning these assets for continued development under an integrated operating model. We couldn’t be more excited about this acquisition.”

For Olenox, the acquisition would mark a further extension of its acquire-and-integrate strategy. The company has spent the past year repositioning itself as a vertically integrated energy and infrastructure platform following a comprehensive rebrand from its former Safe & Green Holdings identity. According to the company, the Olenox name is intended to reflect a unified operating model rather than a collection of unrelated assets.

Under the Olenox Industries banner, the business now spans energy development, oilfield services, industrial technology, containerized infrastructure, and monitoring systems. A central element of the rebrand has been the consolidation of subsidiaries into a single operating structure, which management says is designed to improve coordination across divisions and give investors clearer insight into how assets interact operationally and financially.

Energy operations sit at the core of that structure, with three integrated divisions. The oil and gas division focuses on acquiring underdeveloped or distressed properties in Texas, Oklahoma, and Kansas, with an emphasis on improving production from existing wells rather than pursuing exploration-led growth.

The oilfield services division provides well abandonment and environmental reclamation services to third parties, generating steady cash flow while supporting Olenox’s own production assets. A third division, Olenox Technologies, develops proprietary tools such as plasma pulse and ultrasonic cleaning systems aimed at restoring output from underperforming wells.

The proposed acquisition of CPE Gathering’s assets would add a midstream layer to this structure. Olenox has said that aligning gathering, transportation, and terminaling assets with its upstream and services operations could lower per-well costs, improve uptime, and increase overall operating efficiency. By controlling logistics, the company expects to reduce reliance on external providers and capture margin that would otherwise sit outside the organization.

The Omega system is also positioned as a platform for further development. According to Olenox, the assets offer a scalable base for deploying additional technology and services designed to improve reliability and reduce operating expenses. The transportation network gives producers access to multiple storage and blending options, which can be particularly valuable in periods of regional congestion.

The Vivakor transaction highlights Olenox’s emphasis on fee-based revenue streams. Midstream assets typically generate income based on volumes and contracted fees rather than commodity prices, which can help stabilize cash flow during periods of oil market volatility. The take-or-pay structure underpinning the EBITDA figure adds another layer of predictability.

The arrangement also aligns with broader policy discussions around American energy independence and domestic infrastructure investment. By expanding its footprint in established U.S. basins such as the STACK, Olenox is positioning itself as a participant in maintaining and upgrading the systems that move domestic oil from wellhead to market.

For more information, visit the company’s website at www.Olenox.com.

NOTE TO INVESTORS: The latest news and updates relating to OLOX are available in the company’s newsroom at https://ibn.fm/OLOX

• ParaZero entered the Cyprus market via a reseller agreement with homeland security specialist Lella Kentonis
• The firm’s counter-UAS technologies are built for complex, contested, and civilian-dense environments
• These updates underscore ParaZero’s mission to create and deliver scalable, low-collateral drone mitigation as threats move into the cities from the battlefields

ParaZero Technologies (NASDAQ: PRZO) is stepping up efforts targeted at its global expansion strategy as hostile drone threats extend into urban and civilian areas. The company recently announced that a reseller arrangement had been reached with Lella Kentonis Investment Co. Limited, engaging the services of the homeland security specialist as its distributor and integrator in Cyprus. With the agreement, ParaZero now has a strategically important access to European markets where more attention is being given to airspace protection (ibn.fm/ly8kz).

As part of the terms of the agreement, Lella Kentonis is expected to distribute and integrate ParaZero’s counter-UAS product lines into Cyprus’ defense and homeland security ecosystem. The partnership underscores ParaZero’s strategy of partnering with reputable regional players to ease market access while addressing country-specific operational and regulatory requirements. The company’s management emphasized that the partnership streamlines the delivery of mission-critical counter-drone solutions, tailored for national security agencies operating in complex environments.

The Cyprus expansions come as drone defense undergoes a strategic shift. Drone threats once limited to active conflict zones are now emerging near cities, in airports, and at public locations. Advances in drone navigation, including vision-based systems and fiber-optic control, are challenging conventional countermeasures and compelling security agencies to change the way they protect urban airspace.

ParaZero’s technology portfolio is targeted to be a solution for the evolving landscape. The company operates at the nexus of counter-UAS systems designed to effectively intercept hostile drones without leading to casualties associated with firearms or missiles, which are not ideal for civilian environments. The company’s DefendAir system, which leverages net-based interception, is created to neutralize threats in highly populated settings without compromising regulatory compliance, public safety, and operational reliability.

The global counter-UAS market was valued at over $6.5 billion in 2025 and is expected to grow quickly as more governments invest in protecting urban centers. In Europe, the increase in defense spending is pushing up the demand from military organizations and homeland security agencies. The company’s management has highlighted that urban drone defense systems require a more strategic approach than what is obtainable in battlefield solutions.

ParaZero’s reseller agreement in Cyprus highlights how the company is transforming battlefield-tested concepts into usable solutions. Through its partnership with local experts, the company can tailor the solutions to specific locations globally. The strategic move also underscores ParaZero’s broader objective of positioning its technology at the intersection of homeland security, defense, and critical infrastructure protection.

For more information, visit the company website at www.ParaZero.com.

NOTE TO INVESTORS: The latest news and updates relating to PRZO are available in the company’s newsroom at ibn.fm/PRZO

• Safe Pro Group has partnered with Lantronix to establish a framework for the joint development and integration of new chipsets that strengthen the ecosystem of Qualcomm-based drone and vehicle platforms.
• Lantronix will integrate Safe Pro Object Threat Detection (“SPOTD”) AI algorithms and models within the company’s Open-Q(TM) System-on-Module (“SOM”) solutions.
• This integration will help deliver on-device and real-time detection of small explosive threats, without having to rely on being connected to the cloud.

Safe Pro Group (NASDAQ: SPAI), a mission-driven tech company delivering AI-powered defense and security solutions, recently partnered with Lantronix to boost AI-driven edge intelligence for autonomous defense systems (https://ibn.fm/hQjw6).

The agreement creates a scalable framework for the joint development, integration, and commercialization of new chipsets that strengthen the ecosystem of Qualcomm-based drone and autonomous vehicle platforms.

This agreement will see Lantronix integrate Safe Pro Object Threat Detection (“SPOTD”) AI models and algorithms into the company’s Qualcomm-based Open-Q(TM) System-on-Module (“SOM”) solutions. The integration will deliver real-time and on-device detection of small explosive threats like landmines, without being forced to rely on cloud connectivity. 

This not only helps with latency, but also enhances resilience and mission-critical security, in an effort to boost the performance of next-gen unmanned systems.

The companies will collaborate on several commercial and defense drone programs, such as Red Cat Holding’s Teal/Black Widow(TM) quadcopters, which are contracted by the U.S. Army under its Short-Range Reconnaissance (“SRR”) program. This partnership also extends the ecosystem by integrating SPOTD outputs into the U.S. Army’s Tactical Assault Kit (“ATAK”) platform through Lantronix’s secure gateways.

This allows for the scalable distribution of intelligence across vehicles, command posts, and other soldier devices.

Speaking about the agreement, the Chairman of Safe Pro Group, Dan Erdberg said, “Lantronix is empowering real-time intelligence at the edge for a wide array of defense and commercial applications, creating immediate synergies for Safe Pro Group.” He added that, “We look forward to working with the Lantronix team and leveraging their proven experience in supporting critical defense contracts, such as Red Cat’s Teal drones, as we scale our proprietary computer vision technologies to meet the needs of defense users around the world.”

Similarly, Saleel Awsare, President and CEO of Lantronix, also spoke about the partnership and said, “Our partnership with Safe Pro Group furthers this vision, bringing AI-enabled threat detection directly to the edge. Together, we are shaping the future of real-time intelligence where our technology becomes the trusted foundation for defense and autonomous platforms worldwide.”

About Safe Pro Group Inc. (NASDAQ: SPAI)

Safe Pro Group is a tech company that delivers AI-powered solutions to customers in the defense, homeland security, humanitarian, law enforcement, and commercial markets. It provides both ballistic protective gear, as well as a drone-based computer vision technology that identifies and detects small explosive objects in drone images and videos, to provide safer and more efficient field operations.

For more information, visit the company’s website at www.SafeProGroup.com.

NOTE TO INVESTORS: The latest news and updates relating to SPAI are available in the company’s newsroom at https://ibn.fm/SPAI

• The project aligns with Olenox’s broader rebrand and shift toward energy-focused support and service technology operations.
• The pipeline is expected to produce both natural gas liquids (“NGLs”) and dry gas.
• NGLs are positioned as a higher-value output sold into midstream blending markets.
• Dry gas sales may also support on-site power generation through containerized systems.

Olenox Industries (NASDAQ: OLOX) has taken another concrete step in repositioning itself as an energy-centered company, announcing that it has begun the process of recommissioning a 162-mile pipeline to operate as a wet gas system. The pipeline, once back in service, is expected to produce both natural gas liquids (“NGLs”) and dry natural gas, expanding the company’s revenue base beyond upstream production alone (https://ibn.fm/BPVQw).

The recommissioning effort begins with a new pipeline survey, which is currently under way and expected to conclude by mid-February. Completion of the survey is a prerequisite for Olenox to apply for reinstatement of the pipeline’s operating license. Once approved, the company plans to bring the system back online and begin commercial operations.

Unlike a dry gas-only pipeline, a wet gas system allows Olenox to extract NGLs such as ethane, propane, and butane. These products typically command higher margins than dry gas and are widely used in blending lower-grade crude and in petrochemical feedstocks across midstream markets. Olenox has indicated that NGLs will be sold into these established channels, while dry gas will be marketed through open contracts.

In addition to external sales, Olenox plans to use surplus dry gas as feedstock for its containerized generator sets. These systems are designed to produce both base-load and peak power for delivery into the grid. Linking pipeline output to on-site power generation can create a vertically integrated energy loop that can adapt to market conditions.

Management has said that, once fully operational, the pipeline is projected to generate significant annual revenue based on its current sales pipeline. Over time, Olenox expects to expand that contribution by increasing NGL output and scaling power generation capacity. 

The recommissioning initiative comes amid a broader corporate transition. Olenox Industries, formerly Safe & Green Holdings Corp., recently completed a comprehensive rebranding to reflect what management describes as an already-evolved business model. Chief Executive Officer Michael McLaren has characterized the rebrand as an alignment exercise rather than a strategic pivot. 

Under the Olenox Industries banner, the company now spans energy development, oilfield services, industrial technology, and containerized infrastructure. The pipeline project fits squarely within this framework, linking midstream infrastructure with upstream production and downstream power applications.

Within this structure, energy operations occupy a central role. Olenox Corp operates three core divisions. The exploration and production unit focuses on underdeveloped or distressed oil and gas properties in Texas, Oklahoma, and Kansas, with an emphasis on improving output from existing wells rather than pursuing greenfield exploration.

Supporting this activity is an oilfield services division specializing in well abandonment and environmental reclamation. These services are designed to provide steady cash flow while also addressing regulatory and environmental obligations tied to legacy assets. A third division, Olenox Technologies, develops proprietary equipment such as plasma pulse and ultrasonic cleaning systems intended to restore productivity in underperforming wells.

Outside of energy production, Olenox continues to operate Giant Containers, a business founded in 2017 that designs and manufactures containerized systems for industrial and commercial use. These systems play a role in the company’s power generation plans, providing modular platforms that can be deployed near pipeline infrastructure or production sites. The company also operates Machfu Monitoring, which delivers Industrial Internet of Things solutions that connect field assets to enterprise systems through secure networks.

The pipeline recommissioning offers a clearer view of Olenox’s strategy to integrate assets across the energy value chain. Rather than relying solely on upstream production or standalone services, the company is positioning infrastructure such as pipelines and power systems as revenue-generating links between its operating units.

For more information, visit the company’s website at www.Olenox.com.

NOTE TO INVESTORS: The latest news and updates relating to OLOX are available in the company’s newsroom at https://ibn.fm/OLOX

• The company has completed a strategic transformation into a pure-play fusion energy platform anchored by a wholly owned operating subsidiary and a clear long-term commercialization objective.
• Kepler’s Texatron(TM) system is engineered from inception for deployable, infrastructure-grade use rather than laboratory experimentation.
• A Power-as-a-Service commercial model is intended to support recurring, contracted revenue aligned with infrastructure financing principles.
• A broad and expanding intellectual property portfolio underpins technology defensibility and long-duration platform value.
• Rising U.S. baseload electricity demand, particularly from commercial and industrial users, creates a structural backdrop for alternative non-intermittent energy solutions.

Renewal Fuels (OTC: RNWF) (d/b/a American Fusion) is an advanced energy platform company focused on building a scalable, infrastructure-grade fusion energy business through its wholly owned subsidiary, Kepler Fusion Technologies. Following a completed reverse merger with Kepler, the company has repositioned itself around the development and long-term commercialization of deployable fusion power systems designed for real-world industrial and infrastructure use rather than experimental research programs.

The company’s strategy centers on pairing proprietary fusion technology with disciplined governance, intellectual property development, and a public-company operating framework intended to support long-duration value creation. Management has emphasized transparency, regulatory readiness, and institutional credibility as foundational elements alongside continued technical progress.

Renewal Fuels is in the process of transitioning its public identity to American Fusion to reflect its strategic focus on advanced fusion energy infrastructure and commercialization.

The company is based in Southlake, Texas.

Kepler Texatron(TM)

Through wholly owned subsidiary, Kepler Fusion Technologies, the company is developing the Texatron(TM) aneutronic fusion platform, a compact, pulsed fusion system engineered specifically for commercial and infrastructure-grade deployment. Unlike steady-state fusion concepts that prioritize laboratory demonstration, the Texatron(TM) operates in controlled cycles designed to support modular scalability, redundancy, and distributed installation across multiple end markets.

The platform is optimized around a Deuterium–Helium-3 fuel pathway that enables direct electrical energy conversion, reducing reliance on traditional steam cycles and minimizing neutron-related material degradation. This design supports a smaller physical footprint and greater flexibility for deployment in grid-constrained or mission-critical environments such as data centers, industrial facilities, defense installations, and remote locations.

Kepler’s commercialization model is structured around a Power-as-a-Service approach under which the company intends to retain ownership of its fusion units and sell electricity to customers under long-term contractual arrangements. This infrastructure-oriented model is designed to align system deployment with predictable, recurring revenue while allowing for fleet-based scaling over time. The platform is supported by a broad and expanding intellectual property estate encompassing reactor architecture, energy conversion systems, control technologies, manufacturing processes, and deployment methodologies.

Market Opportunity

U.S. electricity demand has re-entered a period of sustained growth following nearly two decades of relative stagnation, according to data from the U.S. Energy Information Administration. After years in which efficiency gains and structural economic shifts largely offset population and economic growth, electricity consumption has increased meaningfully since 2020 and is forecast to continue rising through at least the middle of the decade.

Recent and projected growth is being driven primarily by the commercial and industrial sectors, with data centers, advanced manufacturing, and other power-intensive operations accounting for a disproportionate share of incremental demand. These segments tend to require continuous, non-intermittent electricity supply, placing increased pressure on existing generation and transmission infrastructure.

This shift underscores a growing need for reliable baseload power sources that can be deployed without extensive new transmission build-out and that align with emissions-reduction objectives. Fusion-based energy systems designed for distributed, infrastructure-grade deployment represent a potential long-term solution for meeting rising demand in environments where reliability, resilience, and scalability are critical.

Leadership Team

Richard Hawkins, Chairman and Chief Executive Officer, has overseen the company’s strategic reset, corporate restructuring, and transition toward an advanced fusion energy platform, with responsibility for governance, capital markets strategy, and long-term corporate development.

Brent Nelson, Chief Executive Officer of Kepler Fusion Technologies, brings extensive experience in energy systems and commercialization strategy and leads the development, validation, and deployment roadmap for the Texatron(TM) fusion platform, as well as Kepler’s intellectual property and operating model.

For more information, visit the company’s website at https://americanfusionenergy.com.

NOTE TO INVESTORS: The latest news and updates relating to RNWF are available in the company’s newsroom at https://ibn.fm/RNWF

• Although CTCL may progress slowly in its early stages, it remains a chronic and ultimately progressive disease for many patients.
• Front-line therapies for CTCL remain limited and fragmented.
• Soligenix is advancing a distinct approach to CTCL treatment through the development of HyBryte(TM), also known as SGX301 or synthetic hypericin.

Cutaneous T-cell lymphoma (“CTCL”) remains a cancer with limited treatment options, persistent symptoms and long-term quality-of-life challenges for patients, even decades after its classification as a distinct disease. Despite medical advances in oncology, many people living with CTCL continue to cycle through therapies that offer only partial relief or introduce new burdens. Soligenix (NASDAQ: SNGX) is advancing new treatment approaches focused on improving tolerability and long-term quality of life for patients living with this rare cancer.

CTCL is a rare form of non-Hodgkin lymphoma that primarily affects the skin, most commonly presenting as mycosis fungoides and Sézary syndrome. It is classified as a chronic, often indolent malignancy that can persist for years or decades, with symptoms that include persistent rashes, plaques, tumors, intense itching and skin pain. According to Soligenix, CTCL accounts for approximately 6% of all non-Hodgkin lymphomas, and its early stages frequently resemble benign skin conditions, which can complicate diagnosis and delay appropriate treatment. 

Although CTCL may progress slowly in its early stages, it remains a chronic and ultimately progressive disease for many patients. The Cutaneous Lymphoma Foundation notes that CTCL is not considered curable with current therapies and that treatment typically focuses on disease control, symptom relief and preservation of quality of life rather than cure. Early-stage disease is often managed with skin-directed therapies, while advanced disease frequently requires systemic treatments that can carry significant toxicity. This long-term disease course means patients often undergo multiple treatment regimens over their lifetime, with cumulative physical and psychological burdens. 

Front-line therapies for CTCL remain limited and fragmented. Standard options include topical corticosteroids, phototherapy, retinoids, interferons, chemotherapy and biologic agents, but response durability is often variable. One review highlights that many CTCL therapies offer only temporary disease control and that relapse is common, reinforcing the need for better tolerated, long-term treatment strategies. The same review emphasizes that balancing disease control with quality of life remains a central challenge in CTCL management.

These limitations are compounded by the fact that many systemic therapies used in later-stage disease can cause immunosuppression, fatigue, organ toxicity and infection risk, creating difficult tradeoffs between disease control and patient well-being. The European Society for Medical Oncology has similarly noted that CTCL remains an area of unmet medical need, particularly for therapies that can be safely used over long periods without cumulative harm. 

Against this backdrop, Soligenix is advancing a distinct approach to CTCL treatment through the development of HyBryte(TM), also known as SGX301 or synthetic hypericin. HyBryte is a visible light-activated photodynamic therapy designed specifically for early-stage CTCL. Unlike ultraviolet-based phototherapies, which can carry long-term carcinogenic risk with repeated exposure, HyBryte uses visible light in the red-yellow spectrum to activate the therapeutic compound in the skin, targeting malignant T-cells while minimizing damage to surrounding healthy tissue. 

HyBryte’s nonsystemic design directly addresses many of the tolerability and quality-of-life limitations associated with current CTCL therapies. Because the therapy is applied topically and activated locally, it avoids any meaningful systemic drug exposure that can lead to widespread side effects. Soligenix explains that this localized mechanism is intended to reduce cumulative toxicity and allow for long-term disease management without the risks associated with chronic systemic immunosuppression. 

Clinical data support the potential of this approach. “In the phase 3 FLASH study, HyBryte was shown to be efficacious in early-stage CTCL with a promising safety profile,” said Ellen Kim, MD, director of the Penn Cutaneous Lymphoma Program and lead investigator of the HyBryte FLASH2 study. “CTCL patients are often searching for alternative treatments, with limited options especially for early-stage disease. HyBryte offers a distinct treatment option which patients found extremely useful and continue to specifically request. We look forward to demonstrating the expanded positive impact of the use of HyBryte in a more ‘real-world’ setting.”

HyBryte therapy has received orphan drug and fast track designations from the U.S. Food and Drug Administration, orphan drug designation in Europe and a Promising Innovative Medicine designation from the UK Health Authority, reflecting regulatory recognition of its potential clinical value for a rare cancer with limited treatment alternatives. 

Soligenix’s strategy reflects a broader shift in CTCL care toward therapies that prioritize long-term disease control, tolerability and patient quality of life rather than short-term symptom suppression alone. By focusing on a nonsystemic, skin-directed approach, the company aims to provide patients with a treatment option that can be used safely over extended periods, addressing the chronic nature of the disease rather than treating it as an episodic condition.

This focus is especially relevant given the long diagnostic delays and prolonged treatment journeys many CTCL patients experience. As institutions and leading oncology organizations continue to raise awareness about CTCL misdiagnosis and delayed care, the availability of better tolerated therapies becomes increasingly important for patients who may spend years navigating ineffective or burdensome treatments.

CTCL remains a cancer defined not only by its rarity but by the long-term challenges it imposes on patients’ lives. The absence of curative therapies, the need for chronic disease management and the limitations of existing treatments continue to create a strong case for innovation. Soligenix’s work with HyBryte reflects an effort to move beyond incremental improvements toward therapies designed specifically around patient tolerability, quality of life and long-term usability. As the CTCL treatment landscape evolves, approaches that balance efficacy with safety and sustainability may play a critical role in shaping future standards of care for this underserved patient population.

For more information, visit www.Soligenix.com.

NOTE TO INVESTORS: The latest news and updates relating to SNGX are available in the company’s newsroom at https://ibn.fm/SNGX